Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD9150 + durvalumab + carboplatin + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AZD9150 + durvalumab + carboplatin + nab-paclitaxel is a combination regimen studied in advanced solid tumors. AZD9150 (also known as danvatirsen or ISIS-STAT3Rx) is an antisense oligonucleotide inhibitor that targets Signal Transducer and Activator of Transcription 3 (STAT3), suppressing tumor-related gene expression[5]. Durvalumab (MEDI4736) is a human monoclonal antibody that acts as a checkpoint inhibitor targeting the programmed death-ligand 1 (PD-L1), restoring anti-tumor immune response[1]. Carboplatin is a platinum-based chemotherapeutic that causes DNA crosslinking, leading to apoptosis. Nab-paclitaxel (albumin-bound paclitaxel) is a nanoparticle formulation of paclitaxel, disrupting microtubule function and cell division. This combination is investigated primarily in patients with advanced or recurrent non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck, aiming to maximize antitumor efficacy through immunomodulation and cytotoxic chemotherapy[1][2][4][5].
- Other names
- ISIS-STAT3RxISIS-STAT-3RxISIS-STAT 3RxISIS 481464ISIS481464ISIS-481464albumin-bound paclitaxelMEDI4736MEDI-4736MEDI 4736
02
Targets
DNACD274 (Programmed cell death protein 1 ligand 1)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on AZD9150 + durvalumab + carboplatin + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD9150 + durvalumab + carboplatin + nab-paclitaxel.